Daratumumab, an anti‐CD38 monoclonal antibody, since its incorporation into the treatment paradigm for newly diagnosed multiple myeloma has enhanced overall survival (OS) and progression‐free survival (PFS) in both transplant eligible and ineligible patients [3, 4, 5]. This evidence concerns the gene CD38 and AL amyloidosis.